Manufacturer
9 recalls in our database name SOMERSET THERAPEUTICS LLC as the manufacturing or recalling firm.
Of the 9 recalls from SOMERSET THERAPEUTICS LLC we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 0 (0%) are Severe.
The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.
Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.
Somerset Therapeutics is recalling one lot of Dexamethasone Sodium Phosphate Injection after out-of-specification impurity results at product expiry during long term stability testing.
Somerset Therapeutics is recalling 52,340 vials of Cisatracurium Besylate Injection, 10 mg/5 mL, after out of specification assay results during long term stability testing.
Somerset Therapeutics is recalling 28,660 vials of Cisatracurium Besylate Injection, 200mg/20mL, after out of specification assay results during long term stability testing.
Somerset Therapeutics is recalling 71,310 vials of Cisatracurium Besylate Injection, 20 mg/10 mL, after out of specification assay results during long term stability testing.
Somerset Therapeutics is recalling Atropine Sulfate Ophthalmic Solution due to failed impurity and degradation specifications. No illnesses have been reported.
Somerset Therapeutics is recalling Haloperidol Decanoate injections nationwide due to the potential presence of trace amounts of water in some vials, which may affect product quality.
Somerset Therapeutics is recalling Brimonidine Tartrate Ophthalmic Solution 0.2% due to a slow leaching process from the product label that may impact the product over its shelf life.
Somerset Therapeutics is recalling 383,437 bottles of Brimonidine Tartrate Ophthalmic Solution 0.2% because a slow leaching process from the product label may impact the product over its shelf life.
Somerset Therapeutics is recalling Brimonidine Tartrate Ophthalmic Solution 0.2% due to a slow leaching process from the product label that may impact the product over its shelf life.
Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.
Somerset Therapeutics, LLC.
Source: Wikidata (Q138413149), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.